Ultrahuman’s racing partnership is about more than lap times; the bigger story is the teenage years when female healthspan takes shape.
A late-breaking slot in Boston will bring fresh data on an experimental drug that aims to turn down tau production in the ...
Alamar and Nightingale will hunt rare, low-level proteins in UK Biobank blood for signs of dementia and Parkinson’s long ...
Six-month University of Surrey RCT sees better endothelial function, less arterial stiffness and lower systolic pressure – ...
Emory researchers say a 10-protein plasma signature outperformed the established marker, though it remains a research finding.
A Phase 1 study of MNA-001, which targets TREM2, saw age-linked markers in elderly volunteers shift toward levels seen in ...
L-Nutra Health launches a clinician-led metabolic program in London, built on a patented plant-based diet designed to mimic ...
Why the next breakthroughs in healthy aging may come from the animal kingdom’s overlooked outliers, and from a rat with a genetic twist.
John Hancock and MIT AgeLab’s second index finds no change since 2025, with care the weakest area and community the strongest ...
Mission Therapeutics has begun a 36-patient Phase 1b study of MTX325, a drug aimed at clearing out damaged mitochondria in ...
Latus Bio's Nature Communications paper models how lowering MSH3 could slow somatic instability – and buy years, perhaps decades.
Twelve abstracts head to The Liver Meeting, including a real-world comparison with resmetirom and four on investigational efruxifermin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results